Loading
Latest filing published 24 Jul 2026 for RemeGen Co., Ltd. - H Shares, €198k.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Wen Qingkai, listed as chief executive, has filed trades across 2 companies (mainly through HKEX), most often in RemeGen Co., Ltd. and RemeGen Co., Ltd. - H Shares. Over a trading history stretching from 29 September 2025 to 22 July 2026, the count stands at 20 filings.
The open-market side counts 5 purchases alongside 14 sales for €7.7M. The totals do not cover 7 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 5 purchases and 14 sales.
No cluster: in 5 purchases, no other insider of the company bought within 30 days.
The latest filing, published on 24 July 2026, reports an open-market sale of €4,072 in RemeGen Co., Ltd. - H Shares. The last insider purchase was made public on 15 June 2026, 131 days ago. Typically, a trade is published a median of 6 days after it takes place. This delay matters because a trade only becomes useful information once it is public. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 8 declarations